Revenue Showdown: Zoetis Inc. vs Corcept Therapeutics Incorporated

Zoetis vs Corcept: A Decade of Revenue Growth

__timestampCorcept Therapeutics IncorporatedZoetis Inc.
Wednesday, January 1, 2014265510004785000000
Thursday, January 1, 2015502860004765000000
Friday, January 1, 2016813210004888000000
Sunday, January 1, 20171592010005307000000
Monday, January 1, 20182512470005825000000
Tuesday, January 1, 20193064860006260000000
Wednesday, January 1, 20203538740006675000000
Friday, January 1, 20213659780007776000000
Saturday, January 1, 20224018580008080000000
Sunday, January 1, 20234823750008544000000
Monday, January 1, 20249256000000
Loading chart...

Data in motion

Revenue Growth: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, Zoetis Inc. and Corcept Therapeutics Incorporated have showcased remarkable revenue trajectories over the past decade. Since 2014, Zoetis Inc. has consistently outperformed, with its revenue growing from approximately $4.8 billion to an impressive $8.5 billion by 2023. This represents a robust growth of nearly 78%. Meanwhile, Corcept Therapeutics has also demonstrated significant progress, with its revenue increasing from around $26.6 million in 2014 to $482 million in 2023, marking an extraordinary growth of over 1,700%.

While Zoetis Inc. maintains a commanding lead in absolute revenue, Corcept Therapeutics' rapid growth rate highlights its potential in the market. This revenue showdown underscores the dynamic nature of the pharmaceutical sector, where both established giants and emerging players can thrive.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025